Your browser doesn't support javascript.
loading
The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583.
Chalmers, James D; Badorrek, Philipp; Diefenbach, Claudia; Kögler, Harald; Sauter, Wiebke; Kreideweiss, Stefan; Hohlfeld, Jens M.
Afiliação
  • Chalmers JD; Division of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.
  • Badorrek P; Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
  • Diefenbach C; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Kögler H; Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • Sauter W; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Kreideweiss S; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
  • Hohlfeld JM; Department of Clinical Airway Research, Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hannover, Germany.
ERJ Open Res ; 10(2)2024 Mar.
Article em En | MEDLINE | ID: mdl-38529344
ABSTRACT
Preclinical and phase 1 study results indicate that BI 1291583 is a reversible, highly potent and highly selective CatC inhibitor that markedly inhibits active NSP production in a dose-dependent manner, supporting phase 2 trials in bronchiectasis patients https//bit.ly/47PZ8E5.
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ERJ Open Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: ERJ Open Res Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido